|
1
|
Mamelak AN and Jacoby DB: Targeted
delivery of antitumoral therapy to glioma and other malignancies
with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv.
4:175–186. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang K, Niu L, Bai Y and Le W:
Glioblastoma: Targeting the autophagy in tumorigenesis. Brain Res
Bull. 153:334–340. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gallego O: Nonsurgical treatment of
recurrent glioblastoma. Curr Oncol. 22:e273–e281. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bergaggio E and Piva R: Wild-type IDH
enzymes as actionable targets for cancer therapy. Cancers (Basel).
11:5632019. View Article : Google Scholar
|
|
5
|
Kirkman HN, Galiano S and Gaetani GF: The
function of catalase-bound NADPH. J Biol Chem. 262:660–666.
1987.PubMed/NCBI
|
|
6
|
Itsumi M, Inoue S, Elia AJ, Murakami K,
Sasaki M, Lind EF, Brenner D, Harris IS, Chio IIC, Afzal S, et al:
Idh1 protects murine hepatocytes from endotoxin-induced oxidative
stress by regulating the intracellular NADP(+)/NADPH ratio. Cell
Death Differ. 22:1837–1845. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee SM, Koh HJ, Park DC, Song BJ, Huh TL
and Park JW: Cytosolic NADP(+)-dependent isocitrate dehydrogenase
status modulates oxidative damage to cells. Free Radic Biol Med.
32:1185–1196. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gagné LM, Boulay K, Topisirovic I, Huot ME
and Mallette FA: Oncogenic activities of IDH1/2 mutations: From
epigenetics to cellular signaling. Trends Cell Biol. 27:738–752.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pansuriya TC, van Eijk R, d'Adamo P, van
Ruler M, Kuijjer ML, Oosting J, Cleton-Jansen AM, van Oosterwijk
JG, Verbeke SLF, Meijer D, et al: Somatic mosaic IDH1 and IDH2
mutations are associated with enchondroma and spindle cell
hemangioma in ollier disease and maffucci syndrome. Nat Genet.
43:1256–1261. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pansuriya TC, Kroon HM and Bovee JV:
Enchondromatosis: Insights on the different subtypes. Int J Clin
Exp Pathol. 3:557–569. 2010.PubMed/NCBI
|
|
11
|
Struys EA, Salomons GS, Achouri Y, Van
Schaftingen E, Grosso S, Craigen WJ, Verhoeven NM and Jakobs C:
Mutations in the D-2-hydroxyglutarate dehydrogenase gene cause
D-2-hydroxyglutaric aciduria. Am J Hum Genet. 76:358–360. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Parsons DW, Jones S, Zhang X, Lin JCH,
Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et
al: An integrated genomic analysis of human glioblastoma
multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yan H, Parsons DW, Jin G, McLendon R,
Rasheed BA, Yuan W, Kos I, Haberle IB, Jones S, Riggins GJ, et al:
IDH1 and IDH2 mutations in gliomas. N Engl J Med. 360:765–773.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Balss J, Meyer J, Mueller W, Korshunov A,
Hartmann C and von Deimling A: Analysis of the IDH1 codon 132
mutation in brain tumors. Acta Neuropathol. 116:597–602. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Calvert AE, Chalastanis A, Wu Y, Hurley
LA, Kouri FM, Bi Y, Kachman M, May JL, Bartom E, Hua Y, et al:
Cancer-associated IDH1 promotes growth and resistance to targeted
therapies in the absence of mutation. Cell Rep. 19:1858–1873. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ma QL, Wang JH, Wang YG, Hu C, Mu QT, Yu
MX, Wang L, Wang DM, Yang M, Yin XF, et al: High IDH1 expression is
associated with a poor prognosis in cytogenetically normal acute
myeloid leukemia. Int J Cancer. 137:1058–1065. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Robbins D, Wittwer JA, Codarin S, Circu
ML, Aw TY, Huang TT, Van Remmen H, Richardson A, Wang DB, Witt SN,
et al: Isocitrate dehydrogenase 1 is downregulated during early
skin tumorigenesis which can be inhibited by overexpression of
manganese superoxide dismutase. Cancer Sci. 103:1429–1433. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
DiNardo CD, Jabbour E, Ravandi F,
Takahashi K, Daver N, Routbort M, Patel KP, Brandt M, Pierce S,
Kantarjian H and Manero GG: IDH1 and IDH2 mutations in
myelodysplastic syndromes and role in disease progression.
Leukemia. 30:980–984. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dang L, White DW, Gross S, Bennett BD,
Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et
al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Nature. 462:739–744. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu C, Ward PS, Kapoor GS, Rohle D, Turcan
S, Wahab OA, Edwards CR, Khanin R, Figueroa ME, Melnick A, et al:
IDH mutation impairs histone demethylation and results in a block
to cell differentiation. Nature. 483:474–478. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim
SH, Ito S, Yang C, Wang P, Xiao NT, et al: Oncometabolite
2-hydroxyglutarate is a competitive inhibitor of
alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 19:17–30.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tan F, Jiang Y, Sun N, Chen Z, Lv Y, Shao
K, Li N, Qiu B, Gao Y, Li B, et al: Identification of isocitrate
dehydrogenase 1 as a potential diagnostic and prognostic biomarker
for non-small cell lung cancer by proteomic analysis. Mol Cell
Proteomics. 11:M111 008821. 2012.
|
|
23
|
Reid Y, Storts D, Riss T and Minor L:
Authentication of human cell lines by STR DNA profiling analysis.
Assay Guidance Manual (Internet) Bethesda (MD): Sittampalam GS,
Grossman A, Brimacombe K, Arkin M, Auld D, Austin CP, Baell J,
Bejcek B, Caaveiro JMM, Chung TDY, et al: Eli Lilly & Company
and the National Center for Advancing Translational Sciences; 2013,
May
1–2013
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
van de Merbel AF, van der Horst G, Buijs
JT and van der Pluijm G: Protocols for migration and invasion
studies in prostate cancer. Methods Mol Biol. 1786:67–79. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Rodriguez IP, Chakravarthi BV and Varambally S:
UALCAN: A portal for facilitating tumor subgroup gene expression
and survival analyses. Neoplasia. 19:649–658. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Holland EC: Gliomagenesis: Genetic
alterations and mouse models. Nat Rev Genet. 2:120–129. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nakada M, Nakada S, Demuth T, Tran NL,
Hoelzinger DB and Berens ME: Molecular targets of glioma invasion.
Cell Mol Life Sci. 64:458–478. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ersahin T, Tuncbag N and Cetin-Atalay R:
The PI3K/AKT/mTOR interactive pathway. Mol Biosyst. 11:1946–1954.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gonzalez DM and Medici D: Signaling
mechanisms of the epithelial-mesenchymal transition. Sci Signal.
7:re82014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Popolo A, Pinto A, Daglia M, Nabavi SF,
Farooqi AA and Rastrelli L: Two likely targets for the anti-cancer
effect of indole derivatives from cruciferous vegetables:
PI3K/Akt/mTOR signalling pathway and the aryl hydrocarbon receptor.
Semin Cancer Biol. 46:132–137. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lee HJ, Venkatarame Gowda Saralamma V, Kim
SM, Ha SE, Raha S, Lee WS, Kim EH, Lee SJ, Heo JD and Kim GS:
Pectolinarigenin induced cell cycle arrest, autophagy, and
apoptosis in gastric cancer cell via PI3K/AKT/mTOR signaling
pathway. Nutrients. 10:10432018. View Article : Google Scholar
|
|
34
|
Zhang H, Xu HL, Wang YC, Lu ZY, Yu XF and
Sui DY: 20(S)-protopanaxadiol-induced apoptosis in MCF-7 breast
cancer cell line through the inhibition of PI3K/AKT/mTOR signaling
pathway. Int J Mol Sci. 19:10532018. View Article : Google Scholar
|
|
35
|
Larue L and Bellacosa A:
Epithelial-mesenchymal transition in development and cancer: Role
of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene.
24:7443–7454. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vanhaesebroeck B, Guillermet-Guibert J,
Graupera M and Bilanges B: The emerging mechanisms of
isoform-specific PI3K signalling. Nat Rev Mol Cell Biol.
11:329–341. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Geisbrecht BV and Gould SJ: The human PICD
gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent
isocitrate dehydrogenase. J Biol Chem. 274:30527–30533. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dimitrov L, Hong CS, Yang C, Zhuang Z and
Heiss JD: New developments in the pathogenesis and therapeutic
targeting of the IDH1 mutation in glioma. Int J Med Sci.
12:201–213. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xu X, Zhao J, Xu Z, Peng B, Huang Q,
Arnold E and Ding J: Structures of human cytosolic NADP-dependent
isocitrate dehydrogenase reveal a novel self-regulatory mechanism
of activity. J Biol Chem. 279:33946–33957. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Janku F, Yap TA and Meric-Bernstam F:
Targeting the PI3K pathway in cancer: Are we making headway? Nat
Rev Clin Oncol. 15:273–291. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Birner P, Pusch S, Christov C, Mihaylova
S, Uzeir KT, Natchev S, Schoppmann SF, Tchorbanov A, Streubel B,
Tuettenberg J and Guentchev M: Mutant IDH1 inhibits PI3K/Akt
signaling in human glioma. Cancer. 120:2440–2447. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Noushmehr H, Weisenberger DJ, Diefes K,
Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP,
Bhat KP, et al: Identification of a CpG island methylator phenotype
that defines a distinct subgroup of glioma. Cancer Cell.
17:510–522. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bralten LB, Kloosterhof NK, Balvers R,
Sacchetti A, Lapre L, Lamfers M, Leenstra S, Jonge Hd, Kros JM,
Jansen EEW, et al: IDH1 R132H decreases proliferation of glioma
cell lines in vitro and in vivo. Ann Neurol. 69:455–463. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhu H, Zhang Y, Chen J, Qiu J, Huang K, Wu
M and Xia C: IDH1 R132H mutation enhances cell migration by
activating AKT-mTOR signaling pathway, but sensitizes cells to 5-FU
treatment as nadph and gsh are reduced. PLoS One. 12:e01690382017.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Carbonneau M, Gagné LM, Lalonde ME,
Germain MA, Motorina A, Guiot MC, Secco B, Vincent EE, Tumber A,
Hulea L, et al: The oncometabolite 2-hydroxyglutarate activates the
mTOR signalling pathway. Nat Commun. 7:127002016. View Article : Google Scholar : PubMed/NCBI
|
